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Abstract 
Background: Large Tumor Suppressor 2(LATS2) gene is a putative tumor suppressor 
gene with potential roles in regulation of cell proliferation and apoptosis in lung 
cancer. The aim of this study is to explore the association of aberrant LATS2 
expression with EGFR mutation and survival in lung adenocarcinoma(AD), and the 
effects of LATS2 silencing in both lung AD cell lines. 
Methods: LATS2 mRNA and protein expression in resected lung AD were correlated 
with demographic characteristics, EGFR mutation and survival. LATS2-specific 
siRNA was transfected into four EGFR wild-type(WT) and three EGFR mutant AD 
cell lines and the changes in LATS2 expression and relevant signaling molecules 
before and after LATS2 knockdown were assayed. 
Results: Fifty resected lung AD were included(M:F=23:27, Smokers:non-
smokers=19:31, EGFR mutant:wild-type=21:29) with LATS2 mRNA levels showed 
no significant difference between gender, age, smoking and pathological stages while 
LATS2 immunohistochemical staining on an independent set of 79 lung AD showed 
similar trend. LATS2 mRNA level was found to be a significant independent predictor 
for survival status(Disease-free survival RR=0.217; p=0.003; Overall survival 
RR=0.238; p=0.036). siRNA-mediated suppression of LATS2 expression resulted in 
augmentation of ERK phosphorylation in EGFR wild-type AD cell lines with high 
basal LAST2 expression, discriminatory modulation of Akt signaling between EGFR 
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wild-type and mutant cells, and induction of p53 accumulation in AD cell lines with 
low baseline p53 levels.  
Conclusions: LATS2 expression level is predictive of survival in patients with 
resected lung AD. LATS2 may modulate and contribute to tumor growth via different 
signaling pathways in EGFR mutant and wild-type tumors. (Abstract word count: 250) 
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Introduction  
LATS2 (Large Tumor Suppressor 2), one of the two human homologues of 
Drosophila warts, is a putative tumor suppressor gene which encodes for a 
serine/threonine kinase 
1
. As a component in the Hippo signaling pathway, LATS2 
kinase plays a critical role in controlling organ size development and in coordinating 
cell proliferation and apoptosis 
2,3
. As a putative tumor suppressor gene, LATS2 
displays multiple mechanisms of actions in different cancer cell types, including cell 
cycle regulation by controlling G1/S and G2/M transition 
4,5
, induction of apoptosis 
by down-regulating anti-apoptotic proteins Bcl-2 and Bcl-XL 
6
, as well as 
maintenance of mitotic fidelity and genetic stability by interacting with other 
regulators of cell division, such as p53 
7
 and Aurora kinases 
8-10
. 
Dysregulation of LATS2 functions has been found in different types of tumors. 
The chromosomal location of LATS2 is mapped to 13q11-q12 where there is frequent 
loss of heterozygosity 
11
. In breast cancer, LATS2 mRNA expression was down-
regulated by promoter hypermethylation and this alteration was associated with large 
tumor size, high rate of metastasis and estrogen receptor and progesterone receptor 
negativity 
12
. LATS2 may also play a role in the development of prostate cancer based 
on findings that reduced LATS2 expression occurred in prostate tumors and LATS2 
negatively modulated androgen receptor-regulated gene transcription 
13
. In malignant 
mesothelioma (MM), LATS2 was found to be inactivated in MM cells and this 
inactivation will lead to deregulated cell growth by allowing constitutive activation of 
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the downstream transcription factor of LATS2 in the Hippo pathway, YAP 
14,15
. The 
expression of LATS2 exhibits suppressive effects on mesothelioma cells. 
In non-small cell lung cancer (NSCLC), occasional information has been 
reported on the effects of aberrant expression of LATS2 except its being one potential 
targets for microRNA-135b action to promote lung cancer metastasis
16
. LATS2 
mutations are rare
17,18
 but other mechanisms have been reported to  cause down-
regulation of its expression such as promoter hypermethylation
19
 and micro-RNA 
regulation 
20,21
. The relation between reduced LATS2 expression and lung cancer 
progression, and the underlying mechanisms remain unknown. In addition, we have 
previously found from expression profiling experiments that LATS2 showed 
differential expression between pulmonary adenocarcinomas with wild-type EGFR 
and ones bearing EGFR mutations at exons 18 to 21 
22
. In this study, we further 
validated the differential expression of LATS2 in lung adenocarcinoma (AD) tissues in 
relation to EGFR mutation status, as well as other clinicopathological factors 
including as smoking history and survival status. Furthermore, we silenced LATS2 
expression by siRNA inference in several lung adenocarcinoma cell lines and 
examined LATS2 knockdown effects on EGFR downstream signaling pathways, 
Ras/Erk, PI3K/Akt, as well as p53 network. 
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Materials and Methods 
Human lung adenocarcinoma tissue 
Newly diagnosed of lung adenocarcinoma patients were recruited 
prospectively before planned surgical resection. The protocol for lung cancer surgical 
specimen collection was approved by the Institutional Review Board Research Ethics 
Committee of the University of Hong Kong and Hong Kong Hospital Authority Hong 
Kong West Cluster. Resected lung adenocarcinoma (AD) tissues from Chinese 
patients were included in this study. Upon resection, these tissue samples were 
immediately submerged in RNAlater RNA Stabilization Reagent (Qiagen), frozen in 
liquid nitrogen, and stored at -80°C until RNA extraction. An independent set of 79 
archival paraffin blocks of lung adenocarcinomas with known patient demographics 
including age, gender and EGFR mutation status (but not smoking habits) collected 
successively at the Histopathology Laboratory of the Hong Kong and Sanatorium 
Hospital was used for immunohistochemical studies. All the tumor tissues used were 
collected from patients who underwent resection of lung tumors without prior 
treatment with EGFR tyrosine kinase inhibitors or any other form of anti-cancer 
treatment. 
Human adenocarcinoma cell lines 
Seven AD cell lines were cultured in RPMI 1640(Gibco, USA) supplemented 
with 1% Penicillin-Streptomycin(Gibco, USA) and 2.5% or 10% fetal bovine 
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serum(Gibco, USA). AD cell lines used in this study were HKULC-2, HKULC-4
23
, 
and H1648, H1650, H1975 and H2023 were from John D Minna M.D., University of 
Texas Southwestern Medical Center at Dallas; while PC9 was from PC Yang M.D., 
National Taiwan University. Three AD cell lines with EGFR mutations, which were 
H1975 with double mutations L858R and T790M, PC9 and H1650 bearing EGFR 
deletions at exon 19. 
Direct sequencing for EGFR mutations 
We utilized the historical standard for EGFR mutation testing, directing 
sequencing 
24,25
. In order to enrich tumor cell content, we performed micro-dissection 
on formalin-fixed paraffin-embedded sections before DNA extraction.  Then, exons 
18-21 of EGFR were PCR-amplified by applying respective primers. Purified PCR 
product was analyzed by ABI 3730xl DNA analyzer and sequence data was reviewed 
by Sequence Scanner Software. 
Real time PCR 
Total RNA was extracted from frozen resected lung adenocarcinoma tissues 
by using the RNeasy kit (Qiagen, UK). After reverse transcription of total RNA via 
QuantiTect
®
 kit (Qiagen, UK), 150ng cDNA templates were used to detect LATS2 
mRNA expression by using quantitative real time PCR (RT-qPCR) with the SYBR 
Green I method (Qiagen, UK). The primer sequences for LATS2 mRNA were: 
Forward, 5'-TGGCACCTACTCCCACAG-3', and Reverse, 5'-
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CCAAGGGCTTTCTTCATCT-3' 
26
. The ribosomal 18S gene was chosen as an 
internal control, and the primer sequences were: Forward, 5'-
AGGAATTGACGGAAGGGCAC-3', and Reverse, 5'-
GGACATCTAAGGGCATCACA-3'.  Thermal cycle conditions were: 95°C for 5 
minutes followed by 40 cycles of amplification at 95°C for 15 second per cycle, 58°C 
(LATS2) or 60°C (18S) for 45 seconds and 72°C for 45 seconds. The dissociation 
curve analysis was carried out to exclude non-specific primer dimers. The relative 
expression level was determined as 2
-∆∆Ct
 with relative to a reference sample 
(BS65.2N-KT, an immortalized normal bronchial epithelial cell line). The logarithmic 
values to base of two of these relative expression levels were used in the following 
statistical analysis. 
Immunohistochemistry 
Immunohistochemistry(IHC) of the LATS2 protein was performed on 
formalin-fixed, paraffin-embedded sections of an independent set of 79 paraffin 
blocks of lung AD different from those used for real-time PCR assay above. 
Antigen retrieval was conducted in Tris-EDTA buffer(10mM Tris, 1mM 
EDTA, pH=9) at 95°C for 30 minutes. The goat polyclonal antibody against human 
LATS2(dilution 1:200; Santa Cruz, USA) or negative control mouse IgG1(dilution: 
1:200; Dako, Denmark) was incubated with the sections overnight at 4°C. After 
treating with the rabbit anti-goat/mouse secondary antibodies(dilution 1:400; Dako, 
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Denmark) respectively at 37°C for 30 minutes, the specimens were stained with DAB 
substrate chromogen system(Dako, Denmark) for 5 minutes. Scoring of 
immunohistochemical staining was performed by independent pathologists(Ximing 
Tang and Ignacio I Wistuba) without knowing the clinical annotations of the 
specimens. LATS2 expression H-scores based on the extension (0-100) and intensity 
(0, none; 1+, weak; 2+, moderate; and 3+, strong) of IHC staining was performed by 
two pathologists (X.T. and I.W.). If there is discrepancy between the two pathologists 
concerned, an independent third pathologist in the same laboratory who were not aware of the 
clinical details and previous H-scores by the first two pathologists. A final H score (0–300) 
was obtained by multiplying the intensity (1-3) and reactivity extension (0-100) for 
each case. Mean score was taken for the whole group of samples and samples with H 
scores above mean would be classified as of higher expression levels whereas those 
with H scores below mean would be classified as of lower expression levels. 
Western Blotting 
Whole-cell lysates were prepared in 1X RIPA lysis buffer (Rockland) with 
addition of 1% protease inhibitor cocktail (Sigma). Total protein (80 ug for Akt and 50 
ug for other proteins) was fractionated using SDS-PAGE and then transferred to 
nitrocellulose membranes (ExPro). After blocking with 5% non-fat milk in Tris 
buffered saline, membranes were incubated overnight at 4°C with various primary 
antibodies and then probed with HRP-conjugated secondary antibodies (anti-rabbit or 
anti-mouse, Abcam) for 2 hours at 4°C. Primary antibodies to LATS2, ERK 1/2, p-
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ERK1/2, Akt, p-Akt (T308), p-Akt (S473) and p53 were from Cell Signaling. β-actin 
(Sigma) was used as a loading control. Immune complexes were visualized by using 
ECL detection kit (GE Healthcare, Japan), and the band intensity was quantified by 
Image J software. 
LATS2 siRNA Transfection 
Cells were transfected using the Hiperfect reagent according to the 
manufacturer’s instructions (Qiagen, UK). The target sequence of LATS2 specific 
siRNA (siLATS2) is 5’-CTCCGCAAAGGGTACACTCAA-3’, and 5nM siRNA was 
added to silence LATS2. One negative control siRNA (Qiagen, UK) was also included. 
Cultured cells were harvested for RNA or protein extraction at baseline and at 48 
hours. 
Statistical Analysis 
Data were analyzed with SPSS 18.0 software. Differences between groups 
were estimated using the Chi-squared test, the Student’s t test, or the log-rank test. 
Disease-free survival (DFS) and overall survival (OS) curves were calculated by the 
Kaplan-Meier method. Stepwise multiple regression models were built to determine 
the clinical parameters that independently predict either PFS or OS. Log rank tests 
were used to compare cumulative survival between different groups. All p values 
were two-sided and p < 0.05 was considered statistically significant. Cox proportional 
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regression model was applied for multivariate analysis. A probability level of 0.05 
was used to determine statistical significance. 
 
Results 
Demographics of lung cancer patients 
Fifty patients were recruited prospectively before they underwent surgical 
resection, with 23 (46.9%) male and 26 (53.1%) female patients and with age range of 
38 to 88 years (mean ± S.D.; 64.1±9.2 years). The ratio of non-smokers (61%) to ex- 
or current smokers (39%) was around 2 to 1. 28 tumors were EGFR wild-type (57%) 
with no mutation at exons 18 - 21 while 21 were EGFR mutants that showed at least 
one EGFR mutation in exons 18 to 21 (43%).  The details can be found in Table 1. 
LATS2 mRNA Expression in lung AD patients 
AD tissue samples expressing LATS2 mRNA at levels above the mean 
expression level(6.3; range 0-13.1) were assigned to the high expression group(mean 
expression value 9.4, n=23), and samples with expression less than the mean value 
were considered as the low expression group(mean expression value 3.6, n=26). 
 LATS2 mRNA levels showed no significant differences between different 
clinical parameters, including gender, age, smoking history, pathological stage and 
EGFR mutation status (Table 1). Survival analysis indicated that high LATS2 
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expression group had significantly longer disease-free survival (DFS) (p=0.002, 
Figure 1A) and overall survival (OS) (p=0.041, Figure 1B) than the low LATS2 
expression group. Furthermore, LATS2 mRNA levels correlated with DFS (partial 
correlation ratio, 0.37; p=0.012). Multivariate analysis further confirmed that LATS2 
mRNA level was a significant prognostic factor for survival status (DFS: hazard ratio, 
0.221; p=0.003; OS: hazard ratio, 0.238; p=0.036) independent of age, gender, 
smoking history and staging (Table 2). Meanwhile, pathological stage (hazard ratio, 
5.102; p=0.009), as well as the presence of EGFR mutations (hazard ratio, 0.207; 
p=0.006) were also significant prognostic factor of DFS (Table 2). When dividing 
samples based on both EGFR mutation status and LATS2 level, patients with wild-
type EGFR as well as expressing low LATS2 expression displayed poor DFS (Figure 
1C). Inferior DFS was also observed in non-smokers exhibiting low LATS2 levels 
(Figure 1D). 
LATS2 protein expression in lung AD tumors 
Immunohistochemistry (IHC) staining on the independent set of 79 paraffin 
blocks of AD indicated that LATS2 protein was expressed at relatively low levels in 
both the cytoplasm and the nucleus(Figure 2C). After excluding 16 cases with zero H-
score in both compartments, paired test revealed that LATS2 protein expression was 
significantly higher in the cytoplasm than in the nucleus(p<0.001). There was an 
association between LATS2 IHC scores in the cytoplasm and gender with EGFR 
mutation status, in which female patients with EGFR mutations displayed modestly 
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low levels of LATS2 cytoplasm expression(p=0.031). In males, EGFR wild-type 
cohort expressed slightly higher cytoplasmic staining of LATS2. These observations 
with LATS2 IHC were consistent with the findings of LATS2 expression at mRNA 
levels among gender with EGFR mutation status groups in a different set of tumor 
specimens with real-time PCR assay done as described in the previous section. 
Nuclear LATS2 expression levels were generally low and no remarkable difference 
was found between all the clinical parameters examined. 
LATS2 mRNA expression in AD cell lines 
Before transfection, LATS2 protein levels were quantified in each cell line (Figure 
2A). Basal LATS2 expression in H2023, HKULC-2 and H1650 were much higher, 
while H1648, HKULC-4, H1975 and PC9 exhibited relatively lower expression levels 
of LATS2. After being transfected with LATS2-specific siRNA (siLATS2) or Negative 
Control siRNA (siCont), LATS2 expression was successfully silenced in all cell lines 
confirmed with  reduced levels of LATS2 protein (Figure 2B). 
LATS2 modulates ERK pathway in the EGFR wild-type AD cell lines with high 
LATS2 expression 
After successfully silencing LATS2 expression in AD cell lines, we first examined for 
changes in phosphorylation of mitogen-activated protein kinase, ERK1/2 (Figure 3A). 
In most of the AD cell lines studied except for H1975 in which we failed to detect the 
activation of ERK1/2, the levels of phosphorylated ERK1/2 did not alter significantly 
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with LATS2 silencing. Nevertheless, a modest increase in the phosphorylation status 
of ERK1/2 was observed in H2023.  
LATS2 knockdown differentially influences Akt activation in different lung AD 
cell lines 
As another EGFR-activated signaling cascade, Akt pathway could also be 
modulated by LATS2 kinase. siRNA silencing of LATS2 increased levels of Thr308-
phosphorylated Akt in H2023 (Figure 3B). Since phosphorylation of Akt at Thr308 
could enhance Akt activity, relatively high basal LATS2 expression in this cell lines 
would inhibit Akt activation. Similar to the situation of ERK activity, LATS2 
knockdown did not affect Akt phosphorylation in neither HKULC-4 which expressed 
very low level of LATS2 nor cell lines, PC9 and H1975, with EGFR mutations. 
Phosphorylation at Ser473, which contributes to maximal Akt Activity, was 
also improved by LATS2 knockdown in HKULC-2 cells (Figure 3C). Together with 
above results, LATS2 might diminish Akt activation in H2023 and HKULC-2 cells. 
Both cell lines showed high LATS2 expression at baseline. In H1650, the addition of 
LATS2 siRNA slightly reduced the level of phosphorylated Akt at Ser473. Although 
the difference was not significant, it was still plausible that LATS2 may differentially 
influence Akt activation and the regulation might be independent of EGFR mutation 
status. 
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Silencing of LATS2 induces p53 accumulation in lung AD cell lines with low basal 
p53 levels 
Previous reports have indicated that LATS2 is able to stabilize p53 thus 
facilitating p53-dependent checkpoint response to mitotic stress in breast cancer and 
osteosarcoma cells ely. However, in HKULC-2 cells, LATS2 knockdown markedly 
increased total p53 levels (Figure 3D), suggesting that, instead of inducing p53 
accumulation, LATS2 may actually downregulate p53 protein expression in these cells. 
Noticeably, HKULC-2 cells expressed very low amount of p53 at baseline (Figure 
3D). Another two cell lines, HKULC-4 and H1650, which also exhibited low basal 
p53 expression, LATS2 silencing likewise enhanced p53 levels although the 
differences were not statistically significant. 
 
Discussion 
In this study, we demonstrated that low LATS2 expression was an independent 
and significant predictor of poor overall survival. Furthermore, expression of LATS2 
correlated with DFS of these lung adenocarcinoma patients (partial correlation ratio, 
0.37; p= 0.012). These findings suggested that LATS2 may express tumor suppressive 
effects in lung adenocarcinoma.  
In this study, patients with tumors harboring EGFR mutations exhibited longer 
median DFS than those with wild-type EGFR (median DFS: 33.4 vs. 27.2 months, 
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respectively; p=0.006). None of the recruited patients received TKI treatment. Other 
than complete resection for most of these early stage tumors, no treatment 
intervention was apparent. The influence of EGFR gene mutation on prognosis as 
shown in this study deserves further investigation. This unusual observation may stem 
from differences in ethnicity and pathological stage of recruited patients, as well as 
different detection methods of EGFR mutations, compared to reported data 
27-29
 
30-32
. 
Since wild type EGFR also significantly predicted inferior DFS, it is not surprising 
that tumors with wild type EGFR and low LATS2 expression exhibited the shortest 
DFS (overall p=0.004, Figure 1C). In non-smokers, in which EGFR mutations are 
more common, significant difference in DFS was still observed between two LATS2 
expression groups (p = 0.010, Figure 1D). Similar observation has been made before, 
that knockdown of YAP (Yes kinase-associated protein), whose functions can be 
inhibited by LATS2, sensitizes cancer cells to EGFR-TKI erlotinib
33
. Further studies 
are warranted to investigate the relationships between LATS2 expression levels and 
therapeutic responses of these atients.  
Immunohistochemistry suggested that AD tumors expressed LATS2 in both 
cytoplasm and nu leus. During interphase, LATS2 mainly remained in the cytoplasm, 
especially localized to the centrosome 
8
. After phosphorylated by Aurora A kinase 
during mitosis, LATS2 could translocate to the chromosome and the central spindle, 
thus modulating chromosome segregation and cytokinesis 
9,10,34
. To date, the best 
characterized function of LATS2 is the regulation of YAP/TAZ proto-proteins via 
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canonical Hippo signaling mainly in breast, colon and hepatic cancers as well as  in 
malignant pleural mesothelioma 
15,35,36
 but not lung adenocarcinomas. LATS2 might 
still plays critical roles in non-canonical Hippo signaling and even in Hippo 
independent pathways, such as the G-protein-coupled receptor (GPCR) signaling 
37,38
 
and the K-ras/Raf-1 axis 
39,40
. The exact roles, as well as the relationship between the 
subcellular localization and the biological functions of LATS2, in lung 
adenocarcinomas need further exploration. 
Our data suggested that LATS2 can suppress ERK signaling in EGFR wild-
type lung adenocarcinoma cell lines with high basal LATS2 expression. Another study 
conducted in HeLa cells identified three down-regulated genes in siRNA-LATS1/2-
treated cells, namely SPRED1, SPRY2 and SPRY4 
41
. These three proteins act as 
negative regulators of the pathway
42-45
, indicating that LATS2 might inhibit ERK 
activation through regulating some members of the Sprouty proteins. Additionally, as 
an upstream activator of ERK1/2, any change in Ras protein levels after silencing of 
LATS2 may contribute to observed alterations in ERK1/2 activities. However, in 
siLATS2-treated H2023, no detectable change in Ras protein expression was observed 
(Figure 4). This implies that LATS2 regulate ERK phosphorylation via other 
mechanisms in H2023. It is mentionable that, in most of lung AD cell lines studied 
LATS2 knockdown induced Ras protein expression (Figure 4). The consequence of 
this modulated Ras expression by LATS2 needs further investigation. 
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The regulation of LATS2 on Akt signaling was more complicated and 
independent of EGFR mutation status. In two EGFR wild-type cell lines (H2023 and 
HKULC-2), LATS2 could reduce Akt activation by inhibiting Akt phosphorylation at 
either Thr308 or Ser473. This alternation may probably result from the ability of 
LATS2 to maintain the protein phosphatase-2A catalytic subunit (PP2A-C) level 
39
 
which in turn leads to dephosphorylation of Akt Thr308 
46
. On the other hand, the 
interaction between LATS2 and Akt may be reciprocal and linked by mammalian 
sterile 20-like kinase-1 (Mst1). Apart from an upstream activator of LATS2, Mst1 has 
been reported to function as an inhibitor of Akt 
47
, and, meanwhile, Akt signaling leads 
to phosphorylation of Mst1 at Thr120 and limits Mst1-mediated tumor suppressive 
functions 
48,49
. The role of LATS2 in this network deserves further study. However, 
LATS2 may also positively modulate Akt activity since silencing of LATS2 in H1650 
triggered a mild decrease in the levels of phosphorylated Akt. As H1650 exhibits loss 
of PTEN gene 
50
 and constitutive activation of Akt, downregulation of LATS2 in this 
cell line, which may in turn inhibit Akt activity, is possible to compensate this 
abnormal signaling transduction. 
In this study, LATS2 may suppress p53 expression, which is contradictory to 
previous studies that LATS2 can cause p53 induction in response to mitotic apparatus 
damage 
7
  as well as oncogenic activation 
51
. That may be partially explained by the 
absence of mitotic or oncogenic stress introduced to cells in this study. On the other 
hand, in NSCLC tumors, downregulated LATS2 mRNA levels have been found to be 
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highly correlated with lower expression of Mdm2 which leads to p53 ubiquitination 
and degradation 
17,18
, implying that diminished LATS2 expression might positively 
regulate p53 protein level, as seen in HKULC-2, HKULC-4 and H1650. All of three 
cell lines express very low amount of p53 at baseline, while two of them, HKULC-2 
and H1650, show relatively high basal LATS2 levels. So it is reasonable to deduce that 
the low basal p53 expression may partially result from the corresponding high basal 
expression of LATS2. Additionally, based on two studies that Snail has been found to 
suppress p53 in A549 lung carcinoma cell line 
52
 and LATS2 can act as a positive 
regulator of Snail1 protein 
53
, we could speculate that LATS2 may negatively mediate 
p53 activity through Snail. Further research can include these two candidates, MDM2 
and Snail, to disclose the comprehensive interaction between LATS2 and p53 in lung 
adenocarcinoma cells. Moreover, since silencing of LATS2 would induce p53 
accumulation, we might postulate that LATS2 is linked to drug sensitivity through 
regulation of p53-mediated processes 
54
. 
In conclusion, relatively higher level of LATS2 gene correlates with the better 
survival in patients with early stage resected lung AD. In vitro LATS2 knockdown 
suggested that this differential expression could impact EGFR-activated signaling 
network, particularly in high LATS2 expression group, and p53 pathway. LATS2 also 
appeared to modulate different signaling pathways via phosphorylated ERK or Akt in 
EGFR wild-type and EGFR mutant lung AD cell lines respectively. Thus, LATS2 
gene expression in lung AD patients warrant further investigations for being a 
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potential biomarker for survival status in lung cancer patients of both early and 
advanced stages as well as the role of LATS2 expression in modulating different 
signaling pathways in either EGFR mutant or EGFR wild-type lung cancer. 
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Figure Legends 
Figure 1: Survival analysis of disease-free survival (DFS) and overall survival (OS). 
A) Significant difference in disease-free survival between high and low LATS2 
expression groups was present. The p-value was estimated by the log-rank test. B) AD 
patients with high LATS2 expression had a significantly better overall survival than 
those expressing low LATS2. .  C) Cox regression analysis demonstrated that patients 
in the wild type EGFR together with low LATS2 expression group exhibited the wors  
DFS. D) In non-smoker patients, high LATS2 expression is a significant predictor of 
better DFS. 
Figure 2: LATS2 protein expression in AD tumors and cell lines. A) Before 
transfection, LATS2 protein expression was measured in each cell lines. B) Cells were 
transfected with siRNA for LATS2 (siLATS2), Negative Control siRNA (siCont) or 
none (Mock Control) for 48hr. Number below each blot indicates fold change to mock 
control (n=3). C) Immunohistochemistry staining of LATS2 expression in clinical 
samples of AD. Female cases bearing EGFR mutations had moderately lower 
expression of LATS2 in the cytoplasm (mean expression value, 77.7 vs. 92.5, p = 
0.031). 
Figure 3: The effects of LATS2 silencing on ERK activation, Akt phosphorylation and 
p53 level. Cells were transfected with siRNA for LATS2 (siLATS2), Negative Control 
siRNA (siCont) or none (Mock Control) for 48hr. Cellular lysates were analyzed by 
Western blotting with the indicated antibodies. Number below each blot indicates fold 
change to mock control (n=3). One asterisk indicates p<0.05 determined by Student’s 
t test. A) Changes in phosphorylated ERK levels in cell lines after 48-hour 
transfection with siRNAs described above. B) Analysis of Thr308-phosphorylated Akt 
levels in cells after transfected with siRNAs described above. C) Levels of Ser473-
phosphorylated Akt in HKULC-2, H1648 and H1650 cells with or without LATS2 
knockdown. D) The top left picture showed the basal levels of p53 in different cell 
lines. Modulation of p53 levels in these cells after transfected with siRNAs described 
above was demonstrated in the lower left picture and in the graph. 
Figure 4: Modulation of Ras expression by LATS2. A) Cells were transfected with 
siRNA for LATS2 (siLATS2), Negative Control siRNA (siCont) or none (Mock Control) 
for 48hr. Cellular lysates were analyzed by Western blotting with the indicated 
antibodies. Number below each blot indicates fold change to mock control (n=3).  
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Table 1: Patient and tumor characteristics according to LATS2 mRNA expression (A) 
and LATS2 protein expression (B) 
(A) LATS2 mRNA expression 
  High LATS2 Expression Low LATS2 Expression P value 
N (%) 23 (46.9) 26 (53.1) 
 Follow-up Duration (Day), mean ± S.D. 1276 ± 404 
 Gender, n(%), M:F 23:26 0.907 
Male 11 (22.4) 12 (24.5) 
 Female 12 (24.5) 14 (28.6) 
 Age, mean ± S.D. 64.1 ± 9.2 0.336 
 
66.3 ± 7.6 62.2 ± 10.2 
 Smoking, n(%), SM:NS 19:30 0.590 
SM 8 (16.3) 11 (22.4) 
 NS 15 (30.6) 15 (30.6) 
 Stage, n(%), I:II:III 29:12:08 0.709 
Stage I 15 (30.6) 14 (28.6) 
 Stage II 5 (10.2) 7 (14.3) 
 Stage III 3 (6.1) 5 (10.2) 
 In groups 
    
0.706 
Earlier stage (I & II) 20 (40.8) 21 (42.9) 
 Advanced stage (III) 3 (6.1) 5 (10.2) 
 Relapse, n(%) 
    
0.015* 
Yes 7 (14.3) 17 (34.7) 
 No 16 (32.7) 9 (18.4) 
 DFS (Day), median 919 
 
 
1303 746 0.006* 
Death, n(%) 
    
0.044* 
Yes 3 (6.1) 10 (20.4) 
 No 20 (40.8) 16 (32.7) 
 OS (Day), median 1095 
 
 
1364 794 0.059 
EGFR, n(%), Mut:WT 21:28 0.283 
Mutation (Mut) 8 (16.3) 13 (26.5) 
 Wild type (WT) 15 (30.6) 13 (26.5)   
 
B) LATS2 IHC staining 
 
Above mean Below mean P value 
N (%) 32 (50.8) 31 (49.2)   
Gender, n(%), M:F 36:27 0.021* 
Male 18 (36) 18 (36) 
 Female 13 (26) 14 (28) 
 EGFR, n(%), Mut:WT 37:22 0.01* 
Mutation (Mut) 18 (36) 19 (38) 
 Wild type (WT) 11 (22) 11 (22)   
*Statistically significant (p < 0.05) 
Table-revised
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C) EGFR mutation status of samples included in this study 
    
Samples for 
mRNA  
Measurement 
Samples for 
IHC 
EGFR wild-type 28 22 
EGFR Mutation 
Exon 18 4 3 
Exon 19 8 10 
Exon 20 1 1 
Exon 21 7 6 
L858R+T790M 1 1 
Unknown 0 27 
 
Page 29 of 45
Ac
ce
pte
d M
an
us
cri
pt
Table 2: Multivariate analysis of disease-free survival (DFS) and overall survival (OS) 
(Cox proportional regression model) 
Univariate Analysis 
DFS   OS 
HR 95% CI p-value   HR 95% CI p-value 
Gender (female/male) 1.129 0.497-2.566 0.772 
 
2.364 0.769-7.270 0.133 
Age  0.951 0.905-1.000 0.051 
 
1.020 0.956-1.088 0.546 
Smoking History (SM/NS) 1.157 0.477-2.807 0.747 
 
0.561 0.187-1.678 0.301 
Stage (I - II/III) 3.975 1.569-10.071 0.004* 
 
1.040 0.229-4.719 0.960 
EGFR Mutation Status (WT/Mut) 0.577 0.247-1.351 0.205 
 
0.348 0.095-1.268 0.110 
LATS2 expression (low/high) 0.269 0.110-0.662 0.004*   0.281 0.077-1.029 0.055 
        
Multivariate Analysis 
DFS   OS 
HR 95% CI p-value   HR 95% CI p-value 
Gender (female/male) 2.431 0.654-9.039 0.185 
 
2.246 0.448-11.251 0.325 
Age  0.997 0.939-1.058 0.913 
 
1.015 0.933-1.103 0.729 
Smoking History (SM/NS) 2.119 0.564-7.961 0.266 
 
1.482 0.327-6.724 0.610 
Stage (I - II/III) 5.102 1.512-17.208 0.009* 
 
1.832 0.320-10.504 0.497 
EGFR Mutation Status (WT/Mut) 0.207 0.068-0.631 0.006* 
 
0.304 0.071-1.306 0.109 
LATS2 expression (low/high) 0.221 0.081-0.605 0.003*   0.238 0.062-0.908 0.036* 
HR = Hazard Ratio; CI = Confidence interval; SM = Smoker; NS = Non-smoker; WT = Wild type; Mut = Mutant 
 *Statistically significant 
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Highlights
 The expression level of Large Tumor Suppressor 2 (LATS2) gene associate with 
survival in patients with resected lung adenocarcinoma (AD).
 LATS2 kinase may interact with EGFR signaling, such as Erk and Akt pathways.
 High LATS2 expression may suppress p53 expression in lung AD cell lines.
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A H2023 HKULC-2 H1648 HKULC-4 PC9 H1975 H1650
LATS2
Short Exposure
Long Exposure
β-actin
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Mock Control siLATS2 siCont Mock Control siLATS2 siCont
HKULC-4
1 0.28 0.79
H2023
1 0.23 0.89
HKULC-2
1 0.44 1.89
H1648
1 0.15 0.98
H1650
1 0.09 1.00
H1975
1 0.41 1.54
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Negative LATS2 staining
LATS2 staining only in the 
cytoplasm LATS2 staining only in the nucleus
LATS2 staining high in the 
cytoplasm and low in the nucleus
LATS2 staining low in the 
cytoplasm and high in the nucleus
High LATS2 staining in both 
cytoplasm and nucleus
C 
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ptp = 0.031C (Con’t)
Group 1 = Tumors of EGFR 
mutant females (n=21)
Group 2 = Tumors other than 
EGFR mutant females (n=38)
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ERK
Total-ERK ß-actin
Mock
Control
siLATS2 siCont
Mock
Control
siLATS2 siCont
Mock
Control
siLATS2 siCont
H2023
1 1.28 0.86 1 1.04 0.97
HKULC-2
1 0.91 1.08 1 0.98 1.16
H1648
1 0.84 1.21 1 1.08 1.14
HKULC-4
1 0.86 0.82 1 0.93 0.99
H1650
1 0.98 1.04 1 1.06 1.13
PC9
1 1.38 1.08 1 0.91 0.93
A
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*
A (Con’t)
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p-Akt(T308) Total-Akt ß-actin
Mock
Control
siLATS2 siCont
Mock
Control
siLATS2 siCont
Mock
Control
siLATS2 siCont
H2023
1 1.80 0.77 1 0.96 1.01
HKULC-4
1 1.22 0.99 1 1.04 1.04
PC9
1 1.62 1.54 1 0.91 0.96
H1975
1 0.92 0.78 1 0.97 0.95
B
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ptp-Akt(S473) Total-Akt ß-actin
Mock
Control
siLATS2 siCont
Mock
Control
siLATS2 siCont
Mock
Control
siLATS2 siCont
HKULC-2
1 0.73 0.22 1 0.95 1.18
H1648
1 1.48 1.74 1 0.91 1.01
H1650
1 1.07 1.47 1 0.92 1.01
C
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C (Con’t)
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H2023 HKULC-2 H1648 HKULC-4 PC9 H1975 H1650
p53
β-actin
p53 ß-actin
Mock
Control
siLATS2 siCont Mock Control siLATS2 siCont
H2023
1 0.92 0.90
HKULC-2
1 1.17 0.61
D
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ptRas ß-actinMock
Control
siLATS2 siCont Mock Control siLATS2 siCont
H2023
1 0.97 1.10
HKULC-2
1 1.09 0.72
H1648
1 1.04 0.79
HKULC-4
1 1.13 0.81
H1650
1 1.05 0.67
H1975
1 0.94 0.64
